Should I buy or sell Bausch + Lomb stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bausch + Lomb in the last twelve months. There are currently 5 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BLCO shares. View BLCO analyst ratings or view top-rated stocks .

What is Bausch + Lomb's stock price target for 2024?

10 analysts have issued twelve-month price targets for Bausch + Lomb's stock. Their BLCO share price targets range from $16.00 to $25.00. On average, they expect the company's share price to reach $19.68 in the next twelve months. This suggests a possible upside of 36.8% from the stock's current price. View analysts price targets for BLCO or view top-rated stocks among Wall Street analysts .

How have BLCO shares performed in 2024?

Bausch + Lomb's stock was trading at $17.06 at the start of the year. Since then, BLCO shares have decreased by 15.7% and is now trading at $14.39. View the best growth stocks for 2024 here .

Are investors shorting Bausch + Lomb?

Bausch + Lomb saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 1,500,000 shares, an increase of 22.0% from the March 15th total of 1,230,000 shares. Based on an average trading volume of 436,800 shares, the days-to-cover ratio is presently 3.4 days. Currently, 3.9% of the shares of the company are sold short. View Bausch + Lomb's Short Interest .

When is Bausch + Lomb's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our BLCO earnings forecast .

How can I listen to Bausch + Lomb's earnings call?

Bausch + Lomb will be holding an earnings conference call on Wednesday, May 1st at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 919-882-2331 with passcode "49631".

How were Bausch + Lomb's earnings last quarter?

Bausch + Lomb Co. (NYSE:BLCO) released its earnings results on Wednesday, February, 21st. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.17 by $0.07. The firm earned $1.17 billion during the quarter, compared to analysts' expectations of $1.11 billion. Bausch + Lomb had a negative net margin of 6.27% and a positive trailing twelve-month return on equity of 3.70%. The firm's quarterly revenue was up 17.8% compared to the same quarter last year. During the same quarter last year, the company posted $0.23 EPS.

What ETFs hold Bausch + Lomb's stock?

ETFs with the largest weight of Bausch + Lomb (NYSE:BLCO) stock in their portfolio include Ballast Small/Mid Cap ETF (MGMT) . First Trust US Equity Opportunities ETF (FPX) .

What guidance has Bausch + Lomb issued on next quarter's earnings?

Bausch + Lomb updated its FY 2024 earnings guidance on Wednesday, February, 21st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $4.6 billion-$4.7 billion, compared to the consensus revenue estimate of $6.1 billion.

When did Bausch + Lomb IPO?

Bausch + Lomb (BLCO) raised $788 million in an initial public offering on Friday, May 6th 2022. The company issued 35,000,000 shares at a price of $21.00-$24.00 per share.

Who are Bausch + Lomb's major shareholders?

Bausch + Lomb's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Renaissance Capital LLC (0.01%).

How do I buy shares of Bausch + Lomb?

Shares of BLCO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSE:BLCO

Bausch + Lomb (BLCO) Stock Price, News & Analysis

→ Chances are you know the firms on this list (From WealthPress) (Ad)

Free BLCO Stock Alerts

$14.39

+0.07 (+0.49%)

(As of 10:13 AM ET)

Compare

Today's Range: $14.31
▼
$14.44
50-Day Range: $14.03
▼
$17.60
52-Week Range: $13.62
▼
$21.95

Volume: 12,057 shs
Average Volume: 476,367 shs
Market Capitalization: $5.06 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $19.68

Get Bausch + Lomb alerts:

Bausch + Lomb MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 36.8% Upside
$19.68 Price Target
Short Interest: Healthy
3.92% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.37
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 35.38%
From $0.65 to $0.88 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.72 out of 5 stars

Medical Sector

407th out of 918 stocks

Ophthalmic Goods Industry

4th out of 7 stocks

3.3

Analyst's Opinion

Consensus Rating
Bausch + Lomb has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 5 buy ratings, 5 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Bausch + Lomb has only been the subject of 4 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
3.92% of the float of Bausch + Lomb has been sold short.
Short Interest Ratio / Days to Cover
Bausch + Lomb has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Bausch + Lomb has recently increased by 21.95%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Bausch + Lomb does not currently pay a dividend.
Dividend Growth
Bausch + Lomb does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BLCO.

2.4

News and Social Media Coverage

News Sentiment
Bausch + Lomb has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Bausch + Lomb this week, compared to 3 articles on an average week.
Search Interest
Only 3 people have searched for BLCO on MarketBeat in the last 30 days. This is a decrease of -70% compared to the previous 30 days.
MarketBeat Follows
3 people have added Bausch + Lomb to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Bausch + Lomb insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 11.07% of the stock of Bausch + Lomb is held by institutions.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Bausch + Lomb are expected to grow by 35.38% in the coming year, from $0.65 to $0.88 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Bausch + Lomb is -19.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Bausch + Lomb is -19.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
Bausch + Lomb has a PEG Ratio of 1.38. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Bausch + Lomb has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Special FREE offer on stock hotsheets

These sheets tell you the exact day you should consider buying a stock… And the exact day you should consider selling it… All based on TEN YEARS of historic data and trends. For example, like January 6th through the 12th with Apple… It’s gone up every single year for the last decade. Or like May 26th through June 11th with LULU… Again - it’s gone up every single year for the last decade. Then there’s July 1st through the 21st with Walmart… What happened to WMT?

Click here and I’ll show you

About Bausch + Lomb Stock (NYSE:BLCO)

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

BLCO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BLCO Stock News Headlines

April 18, 2024 | finance.yahoo.com

Bausch + Lomb Corporation (BLCO)

April 18, 2024 | businesswire.com

Bausch + Lomb Reports More Than 84 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through Innovative Recycling Programs

April 19, 2024 | Darwin (Ad)

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

April 15, 2024 | businesswire.com

Bausch + Lomb Will Release First-Quarter 2024 Financial Results on May 1

April 14, 2024 | americanbankingnews.com

Bausch + Lomb (NYSE:BLCO) Stock Price Down 6.5%

April 11, 2024 | msn.com

Bausch Health gains after appeals court affirms ruling in Norwich patent case (update)

April 9, 2024 | markets.businessinsider.com

Bausch + Lomb’s Strong Market Position and Innovative Pipeline Justify Buy Rating

April 2, 2024 | markets.businessinsider.com

Bausch + Lomb’s Strong Position in Dry Eye Market Prompts Buy Rating

April 19, 2024 | Darwin (Ad)

Explore the Future: Unlock the Top 3 AI Stocks for 2024 Report

Eager to enhance your investment strategies with foresight? Dive into our intriguing report: "The Top 3 AI Stocks for 2024." Gain profound insights and uncover the secrets with just a click! Why This Report Is Your Gateway to Success: * Expertly Curated: Delve into the AI stocks handpicked by our market analysts for 2024's success story. * In-Depth Analysis: Dive deep into comprehensive profiles and explore each top stock. (**By clicking the link you are subscribing to The Wealthiest Investor Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy. Full disclosures found here.)

March 29, 2024 | nasdaq.com

BLCO Crosses Above Key Moving Average Level

March 16, 2024 | finance.yahoo.com

BLCO Apr 2024 17.500 call

March 7, 2024 | msn.com

Benchmark upgrades Emergent Biosolutions to Buy

February 28, 2024 | finance.yahoo.com

Bausch + Lomb Announces Appointment of Karen L. Ling to Board of Directors

February 26, 2024 | markets.businessinsider.com

Barclays Maintains Equal-Weight Rating for Bausch & Lomb: Here's What You Need To Know

February 26, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (IDXX), Bausch + Lomb Corporation (BLCO) and Eli Lilly & Co (LLY)

February 23, 2024 | msn.com

Bausch + Lomb Stock Jumps After Better-Than-Expected Earnings, Guidance

February 23, 2024 | finance.yahoo.com

Bausch + Lomb Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

February 22, 2024 | finance.yahoo.com

BHC Feb 2024 10.000 put

February 22, 2024 | finance.yahoo.com

Bausch + Lomb Corporation (NYSE:BLCO) Q4 2023 Earnings Call Transcript

February 22, 2024 | realmoney.thestreet.com

Bausch + Lomb price target raised by $2 at Wells Fargo, here's why

February 22, 2024 | finance.yahoo.com

Q4 2023 Bausch + Lomb Corp Earnings Call

February 21, 2024 | msn.com

Bausch & Lomb’s stock soars 9% after earnings beat

February 21, 2024 | markets.businessinsider.com

Needham Reaffirms Their Hold Rating on Bausch + Lomb Corporation (BLCO)

February 21, 2024 | msn.com

Eye Care-Focused Bausch + Lomb's Stock Surges On Upbeat Annual Guidance Despite Deeper Losses

February 21, 2024 | msn.com

Bausch & Lomb’s stock soars 11% after earnings beat

February 21, 2024 | reuters.com

Emergent appoints former Bausch + Lomb CEO to head company

February 21, 2024 | msn.com

BLCO Earnings: Bausch + Lomb Outperforms in Q4, Shares Jump

See More Headlines

Receive BLCO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bausch + Lomb and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/21/2024
Today: 4/19/2024
Next Earnings (Confirmed): 5/01/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Ophthalmic goods
Sub-Industry: N/A
Current Symbol: NYSE:BLCO
CUSIP: N/A
CIK: 1860742
Web: www.bausch.com
Phone: 905-695-7700
Fax: N/A
Employees: 13,300
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $19.68
High Stock Price Target: $25.00
Low Stock Price Target: $16.00
Potential Upside/Downside: +36.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.74)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 22.14
P/E Growth: 1.38
Net Income: $-260,000,000.00
Net Margins: -6.27%
Pretax Margin: -4.00%
Return on Equity: 3.70%
Return on Assets: 2.11%

Debt

Debt-to-Equity Ratio: 0.65
Current Ratio: 1.74
Quick Ratio: 1.09

Sales & Book Value

Annual Sales: $4.15 billion
Price / Sales: 1.22
Cash Flow: $1.92 per share
Price / Cash Flow: 7.49
Book Value: $19.72 per share
Price / Book: 0.73

Miscellaneous

Outstanding Shares: 351,400,000
Free Float: N/A
Market Cap: $5.06 billion
Optionable: Optionable
Beta: 0.36

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Mr. Osama A. Eldessouky (Age 52)
Executive VP & CFO
Comp: $1.09M
Dr. Yehia Hashad M.D. (Age 57)
Executive VP of Research & Development and Chief Medical officer
Comp: $1.09M
Mr. Brenton L. Saunders J.D. (Age 54)
CEO & Chairman
Mr. Alan Waterhouse CPFA (Age 64)
MBA, Executive VP and Chief Supply Chain & Operations Officer
Mr. Frederick J. Munsch (Age 53)
Senior VP, Controller & Chief Accounting Officer
Mr. A. Robert D. Bailey (Age 61)
Executive VP & Chief Legal Officer
Mr. Jonathon L. Kellerman
Chief Compliance Officer
T.J. Crawford
Chief Communications Officer
Dr. Manisha A. Narasimhan Ph.D. (Age 47)
Chief Corporate Development & Digital Officer
Ms. Asli Gevgilili
Executive VP & Chief Human Resources Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

BLCO Stock Analysis - Frequently Asked Questions

Should I buy or sell Bausch + Lomb stock right now?: 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bausch + Lomb in the last twelve months. There are currently 5 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BLCO shares.
View BLCO analyst ratings or view top-rated stocks.
What is Bausch + Lomb's stock price target for 2024?: 10 analysts have issued twelve-month price targets for Bausch + Lomb's stock. Their BLCO share price targets range from $16.00 to $25.00. On average, they expect the company's share price to reach $19.68 in the next twelve months. This suggests a possible upside of 36.8% from the stock's current price.
View analysts price targets for BLCO or view top-rated stocks among Wall Street analysts.
How have BLCO shares performed in 2024?: Bausch + Lomb's stock was trading at $17.06 at the start of the year. Since then, BLCO shares have decreased by 15.7% and is now trading at $14.39.
View the best growth stocks for 2024 here.
Are investors shorting Bausch + Lomb?: Bausch + Lomb saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 1,500,000 shares, an increase of 22.0% from the March 15th total of 1,230,000 shares. Based on an average trading volume of 436,800 shares, the days-to-cover ratio is presently 3.4 days. Currently, 3.9% of the shares of the company are sold short.
View Bausch + Lomb's Short Interest.
When is Bausch + Lomb's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our BLCO earnings forecast.
How can I listen to Bausch + Lomb's earnings call?: Bausch + Lomb will be holding an earnings conference call on Wednesday, May 1st at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 919-882-2331 with passcode "49631".

How were Bausch + Lomb's earnings last quarter?: Bausch + Lomb Co. (NYSE:BLCO) released its earnings results on Wednesday, February, 21st. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.17 by $0.07. The firm earned $1.17 billion during the quarter, compared to analysts' expectations of $1.11 billion. Bausch + Lomb had a negative net margin of 6.27% and a positive trailing twelve-month return on equity of 3.70%. The firm's quarterly revenue was up 17.8% compared to the same quarter last year. During the same quarter last year, the company posted $0.23 EPS.
What ETFs hold Bausch + Lomb's stock?: ETFs with the largest weight of Bausch + Lomb (NYSE:BLCO) stock in their portfolio include Ballast Small/Mid Cap ETF (MGMT).First Trust US Equity Opportunities ETF (FPX).
What guidance has Bausch + Lomb issued on next quarter's earnings?: Bausch + Lomb updated its FY 2024 earnings guidance on Wednesday, February, 21st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $4.6 billion-$4.7 billion, compared to the consensus revenue estimate of $6.1 billion.
When did Bausch + Lomb IPO?: Bausch + Lomb (BLCO) raised $788 million in an initial public offering on Friday, May 6th 2022. The company issued 35,000,000 shares at a price of $21.00-$24.00 per share.
Who are Bausch + Lomb's major shareholders?: Bausch + Lomb's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Renaissance Capital LLC (0.01%).
How do I buy shares of Bausch + Lomb?: Shares of BLCO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:BLCO) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Bausch + Lomb (BLCO) Stock Price, News & Analysis

Bausch + Lomb MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Bausch + Lomb Stock (NYSE:BLCO)

BLCO Stock Price History

BLCO Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

BLCO Stock Analysis - Frequently Asked Questions

Overall MarketRank^™